Contineum Therapeutics (CTNM) Return on Capital Employed (2024 - 2026)
Contineum Therapeutics' Return on Capital Employed history spans 3 years, with the latest figure at 25.48% for Q1 2026.
- Quarterly Return on Capital Employed rose 456.0% to 25.48% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 25.48% through Mar 2026, up 456.0% year-over-year, with the annual reading at 28.96% for FY2025, 252.0% up from the prior year.
- Return on Capital Employed came in at 25.48% for Q1 2026, up from 30.38% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 0.06% in Q1 2024 to a low of 37.67% in Q3 2025.
- The 3-year median for Return on Capital Employed is 29.52% (2024), against an average of 26.63%.
- Year-over-year, Return on Capital Employed tumbled -3011bps in 2025 and then skyrocketed 456bps in 2026.
- Contineum Therapeutics' Return on Capital Employed stood at 24.89% in 2024, then decreased by -22bps to 30.38% in 2025, then grew by 16bps to 25.48% in 2026.
- Per Business Quant, the three most recent readings for CTNM's Return on Capital Employed are 25.48% (Q1 2026), 30.38% (Q4 2025), and 37.67% (Q3 2025).